You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

daBRAFenib

( da-BRA-fe-nib )
Funding:
Exceptional Access Program
  • daBRAfenib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
  • daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
  • daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Other Name(s): Tafinlar®
Appearance: capsule In various strengths and colours

Patient Info Sheet

Aug 2018

What it is used for

  • Given alone or in combination with another medication for treating a type of skin cancer called melanoma, that has spread to other parts of the body or cannot be removed by surgery
  • Given with another medication for treating a type of non-small cell lung cancer


You might also be interested in